alexa Contact Editorial in Chief: Vaccines and Vaccination Journals
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 
TKS Mukkur Editor-in-Chief
Trilochan Mukkur
Associate Professor
School of Biomedical Sciences
Curtin University of Technology
Australia
 
Biography

Dr. TKS Mukkur is a Fellow of the Australian Society of Microbiology. He conducted research at institutions noted worldwide including Stanford University School of Medicine, Harvard University Medical School and Washington University in St Louis, Missouri, St Louis, USA and he have a total of 105 publications and supervised the research of 30 students [postgraduate + BSc (Hons)] and have held academic and/or research positions in Canadian and Australian organisations including CSIRO and universities. His major research interests are i)Identification of immunomodulatory and bacterial biofilm dispersing agents from traditional medicinal plants of different ethno-botanical origins and to ii)Apply modern life sciences technologies for development of diagnostic assays, discovery of novel antimicrobials and affordable non−invasive vaccines for infectious diseases of humans and animals, using live attenuated bacterial pathogens as vaccines and deliver vectors for heterologous antigens including tumour-associated and tumour-specific antigens.

 
Research Interest

His major research interests are i)Identification of immunomodulatory and bacterial biofilm dispersing agents from traditional medicinal plants of different ethno-botanical origins and to ii)Apply modern life sciences technologies for development of diagnostic assays, discovery of novel antimicrobials and affordable non−invasive vaccines for infectious diseases of humans and animals, using live attenuated bacterial pathogens as vaccines and deliver vectors for heterologous antigens including tumour-associated and tumour-specific antigens.

 
Network
 
Toshi Nagata Editor-in-Chief
Toshi Nagata
Professor
Department of Health Science
Hamamatsu University School of Medicine
Japan
Tel: 81-53-435-2332
Fax: 81-53-435-2332
 
Biography

Toshi Nagata is a professor of Department of Health Science, Hamamatsu University School of Medicine, Hamamatsu, Japan. He has received a PhD in molecular biology in Osaka University, Osaka, Japan in 1989. He had his postdoctoral training during 19891992 at National Institute of Child Health and Human Development NICHD, National Institutes of Health NIH, Bethesda, USA. Then, he was an assistant professor at Department of Parasitology, Yokohama City University, Yokohama, Japan during 1995-1997. Then, he was an associate professor at Department of Microbiology and Immunology, Hamamatsu University School of Medicine, Hamamatsu, Japan during 1997-2006. Since then, he has been a professor of Department of Health Science, Hamamatsu University School of Medicine, Hamamatsu, Japan. He is serving as a reviewer of many reputed journals on immunology and microbiology, etc.

 
Research Interest

T-cell responses against intracellular pathogens DNA vaccination Antigen presentation Genetics of MHC molecules

 
Network
 
Franco M. Venanzi Editor-in-Chief
Franco M. Venanzi
Senior Researcher Professor of Physiology
Group Leader Unit of Translational Biology
University of Camerino
Italy
 
Biography

Franco Maria Venanzi, PhD, is a research professor of Physiology at the University of Camerino (UNICAM) Italy, where is Head of the Laboratory of Translational Biology Laboratory. His research is in the area of cancer vaccines and cancer immunotherapy. Since the mid-90s his research is aimed at developing DNA-based vaccines to treat cancer (e.g. breast cancer and melanoma). He pioneered the development of DNA vaccines against the oncogene HER-2/neu, and his preclinical studies contributed to the progression of the vaccine to the clinical setting. Since the work began he has sought to develop new approaches to further increase the potency of DNA vaccines using immune-stimulatory gene adjuvants. Recently, Prof. Venanzi scientific interest extended to the search of predictive biological markers to enable the selection of cancer patients who are most likely to benefit from dendritic cells-based immunotherapy. Prof. Venanzi serves as reviewer for various journal of oncology and immunology and as scientific consultant for small biotech companies.

 
Research Interest

DNA vaccines, Cancer Vaccines

 
Network
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords